Abstract
The direct cost of medical care for HIV infection-excluding ARVs, viral load and CD4 counts-was assessed for patients who received ARV treatment in Senegal within the framework of the ANRS cohort 1215, between the third and tenth year of follow-up. The average annual direct cost was estimated at 120 <euro>/patient/year; this amount remained stable over the first ten years of treatment follow-up. Biological assessments for routine follow-up account for the majority of these costs (66%), followed by drugs (26%). Given the level of economic poverty facing by families, patients cannot bear such expenses over several years. However, these costs appear low enough to be covered by HIV-treatment programs or included in Universal Health Coverage systems.
| Translated title of the contribution | Assessing the direct cost of medical care for HIV between the third and tenth year of ARV treatment in Dakar |
|---|---|
| Original language | French |
| Pages (from-to) | 292-8 |
| Number of pages | 7 |
| Journal | Societe de Pathologie Exotique. Bulletin |
| Volume | 107 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 21 Jul 2014 |
Keywords
- Adult
- Antiretroviral Therapy, Highly Active/economics
- Cost of Illness
- Drug Costs
- Female
- Follow-Up Studies
- HIV Infections/drug therapy
- HIV-1
- Humans
- Long-Term Care/economics
- Male
- Middle Aged
- Senegal/epidemiology
- Survival Analysis
Research Beacons, Institutes and Platforms
- Humanitarian and Conflict Response Institute
